Stockscreener 앱 받기
0.00
100.00%
-106.91
전일 마감가:
$106.91
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$9.19B
수익:
-
순이익/손실:
$-153.72M
주가수익비율:
0.00
EPS:
-2
순현금흐름:
$-103.81M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$106.93
Verona Pharma Plc Adr Stock (VRNA) Company Profile
명칭
Verona Pharma Plc Adr
전화
011-44-0-2032834200
주소
3 MORE LONDON RIVERSIDE, LONDON
VRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
0.00 | 9.19B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-01 | 개시 | Wolfe Research | Outperform |
| 2025-04-28 | 개시 | TD Cowen | Buy |
| 2025-04-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 개시 | ROTH MKM | Buy |
| 2024-10-03 | 개시 | Wells Fargo | Overweight |
| 2023-05-22 | 재개 | Jefferies | Buy |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-08-26 | 개시 | Piper Sandler | Overweight |
| 2021-09-13 | 개시 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Jefferies | Buy |
| 2020-08-10 | 개시 | Canaccord Genuity | Buy |
| 2019-04-18 | 개시 | BTIG Research | Buy |
모두보기
Verona Pharma Plc Adr 주식(VRNA)의 최신 뉴스
Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives Average Rating of “Hold” from Brokerages - Defense World
US Bancorp DE Has $748,000 Holdings in Verona Pharma PLC American Depositary Share $VRNA - Defense World
VRNA: Cantor Fitzgerald Maintains Overweight Rating with $100 PT - GuruFocus
Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend - Yahoo Finance
Merck completes acquisition of Verona Pharma; VRNA shares delisted from Nasdaq - Investing.com
BioSpace Announces Inaugural 40 Under 40 Winners (2025-10-07) - Seeking Alpha
Verona Pharma (VRNA): A Fresh Look at Current Valuation and Market Expectations - Sahm
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales - Sahm
Verona Pharma stock hits all-time high at 106.91 USD By Investing.com - Investing.com Canada
Court approves MSD’s $10 billion acquisition of Verona Pharma - Investing.com
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales - Benzinga
Verona Pharma stock hits all-time high at 106.91 USD - Investing.com
Is There Still Opportunity in Verona Pharma After Ohtuvayre Approval and 246% Price Surge? - Sahm
VRNA Quantitative Stock Analysis - Nasdaq
Verona Pharma stock reaches all-time high at 106.75 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock reaches all-time high at 106.75 USD - Investing.com India
Verona Pharma shareholders approve $10 billion Merck acquisition - Investing.com
AstraZeneca Asthma Drug Fails COPD Study for a Second Time - Bloomberg.com
Verona Pharma stock hits all-time high at 106.45 USD - Investing.com India
Verona Pharma stock hits all-time high at 106.45 USD By Investing.com - Investing.com Canada
Verona Pharma Extends Severance Benefits Amid Merck Deal - The Globe and Mail
Invesco Ltd. Makes New Investment in Verona Pharma PLC American Depositary Share $VRNA - Defense World
Verona Pharma stock hits all-time high at 106.19 USD By Investing.com - Investing.com Australia
Verona Pharma stock hits all-time high at 106.19 USD - Investing.com
Merck Taps US Investment-Grade Bond Market for Verona Purchase - Bloomberg.com
Verona Pharma stock hits all-time high at 105.86 USD By Investing.com - Investing.com Australia
Verona Pharma stock hits all-time high at 105.86 USD - Investing.com
TRAILBLAZERS TAKE THE STAGE: PM360 TO CROWN LIFE SCIENCES' BRIGHTEST, SEPTEMBER 30 - Seeking Alpha
Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck - MSN
Verona Pharma : Notice of Meetings and Proxy Statement in connection with proposed acquisition of Verona Pharma - MarketScreener
Verona Pharma stock reaches all-time high at 105.54 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock reaches all-time high at 105.54 USD - Investing.com
Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio - MSN
Verona Pharma ADR earnings beat by $0.11, revenue topped estimates - Investing.com Nigeria
Verona Pharma CFO Hahn sells $2.75 million in shares By Investing.com - Investing.com India
Verona Pharma (VRNA) director Ackermann sells $24k in shares - Investing.com
Verona Pharma CFO Hahn sells $2.75 million in shares - Investing.com
Verona Pharma director Cunningham sells shares for $142,057 By Investing.com - Investing.com South Africa
Verona Pharma (VRNA) director Deschamps sells $124,391 in shares - Investing.com India
Verona Pharma director Cunningham sells shares for $142,057 - Investing.com India
VERONA PHARMA PLCADR: Quantitative Momentum Investor Model Ratings - AInvest
Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today - The Globe and Mail
Verona Pharma stock hits all-time high at 105.31 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock hits all-time high at 105.31 USD - Investing.com
Verona Pharma Plc ADR’s Shares Reel: 69.24% Quarterly Revenue Decline Amid 8.93B Market Cap - investchronicle.com
Verona Pharma stock reaches all-time high at 105.0 USD By Investing.com - Investing.com Australia
Verona Pharma Plc Adr (VRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):